U.S. markets open in 1 hour 57 minutes

Natus Medical Incorporated (NTUS)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
32.70-0.20 (-0.61%)
At close: 04:00PM EDT
32.70 0.00 (0.00%)
After hours: 04:10PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected


Previous Close32.90
Bid32.04 x 1300
Ask33.28 x 900
Day's Range32.66 - 32.85
52 Week Range20.90 - 33.93
Avg. Volume531,341
Market Cap1.131B
Beta (5Y Monthly)0.24
PE Ratio (TTM)86.05
EPS (TTM)0.38
Earnings DateAug 03, 2022 - Aug 08, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
-34% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for NTUS

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Natus Medical Incorporated
    NTUS: What does Argus have to say about NTUS?NATUS MEDICAL INC has an Investment Rating of BUY; a target price of $35.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of High; and a Value Subrating of Medium.
    Fair Value
    Economic Moat
    8 days agoArgus Research
View more
  • GlobeNewswire

    Natus Medical Announces First Quarter 2022 Financial Results

    Q1-2022 Key ResultsRevenue (millions)$119.8 • Total revenue increased 4.2% compared to Q1 2021• Generated $8.9 million in operating cash flowGAAP EPS$0.06 Non-GAAP EPS$0.22 MIDDLETON, Wis., May 05, 2022 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ:NTUS) (the “Company” or “Natus”), a leading provider of medical device solutions to screen, diagnose, and treat disorders affecting the brain, neural pathways, and eight sensory nervous systems, today announced financial results for the three


    Natus Medical Soars. It’s Being Taken Private by ArchiMed for $1.2 Billion.

    Shares of Natus Medical were soaring Monday after the company announced it would be acquired by investment firm ArchiMed for approximately $1.2 billion. Natus (ticker: NTUS ) is a maker of medical devices for diagnosing and treating disorders affecting the brain and nervous systems. ArchiMed will pay Natus shareholders $33.50 in cash for each share of common stock they own, a 29% premium to the stock’s closing price on April 14.